Shutdown Delay: NIH Rushes Diabetes Grant Secrecy Session
Published Date: 11/28/2025
Notice
Summary
The NIH’s Center for Scientific Review is holding a closed virtual meeting on December 16, 2025, to review important grant applications about Type 1 Diabetes research. This meeting was delayed due to a government shutdown but is now urgent to keep funding on track for vital health studies. Researchers and public health experts are affected as this helps decide who gets money to fight major health issues.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Urgent NIH grant review for Type 1 Diabetes
If you are a researcher or public health expert with an NIH grant application for Collaborative Research Using Samples and Data from Type 1 Diabetes Clinical Studies, the NIH Center for Scientific Review will hold a closed virtual meeting on December 16, 2025, from 11:00 a.m. to 1:00 p.m. to review and evaluate those grant applications. The meeting was delayed by a 43-day government shutdown and is being held urgently so evaluations can be submitted to national advisory councils for timely funding recommendations.
Meeting closed to protect applicant confidentiality
The meeting will be closed to the public under 5 U.S.C. 552b(c)(4) and 552b(c)(6) because discussions could disclose confidential trade secrets, patentable material, or personal information about individuals associated with the grant applications. This keeps applicants' proprietary and personal information private during the review.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14966, Government-Owned Inventions; Availability for Licensing
The National Institutes of Health is offering a new Ebola vaccine invention for companies to license and develop quickly. This vaccine targets the Bundibugyo virus and promises fast and lasting protection, helping stop outbreaks in Central Africa. Businesses interested in licensing should act soon to bring this life-saving tech to market and can contact NIH for details.
Previous / Next Documents
Previous: 2025-21355, Center for Scientific Review; Notice of Closed Meetings
The NIH’s Center for Scientific Review is holding a closed virtual meeting on January 8-9, 2026, to review important grant applications. These meetings keep sensitive info private, protecting trade secrets and personal details. Scientists applying for grants should note this review process, which helps decide who gets funding but doesn’t change any deadlines or money right now.
Next: 2025-21357, Federal and State Current Issues Collaborative; Notice Postponing Meeting
The Federal and State Current Issues Collaborative meeting planned for November 12, 2025, in Seattle is postponed to February 2026 in Washington, DC. This change affects regulators and stakeholders who follow energy rules and coordination. The delay is due to limited travel caused by a pause in federal funding, but the Commission is still up and running.